

7. **Hussain M, Tangen CM, Higano C, et al.** Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). *J Clin Oncol.* 2006; 24(24): 3984–90.
8. **Lozar T, Gersak K, Cemazar M, Kuhar CG, Jesenko T.** The biology and clinical potential of circulating tumor cells. *Radiol Oncol.* 2019; 53(2): 131–47.
9. **Dathathri E, Isebia KT, Abali F, et al.** Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer. *Front Oncol.* 2022; 12: 863472.
10. **de Bono JS, Scher HI, Montgomery RB, et al.** Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res.* 2008; 14(19): 6302–9.
11. **Scher HI, Heller G, Molina A, et al.** Circulating Tumor Cell Biomarker Panel as an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol.* 2015; 33(12): 348–55.
12. **Vasseur A, Kiavue N, Bidard F, Pierga J, Cabel L.** Clinical utility of circulating tumor cells: an update. *Mol Oncol.* 2021; 15(6): 1647–66.
13. **Čapoun O, Soukup V, Mikulová V, et al.** Cirkulující nádorové buňky a prognóza karcinomu prostaty. *Čas. Lék. čes.* 2014; 152: 72–77.
14. **Petrelli F, Cabiddu M, Coinu A, et al.** Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies. *Acta Oncol.* 2015; 54(7): 961–70.
15. **Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL.** Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association with Survival and Activated Vascular Endothelial Growth Factor Pathway A Report of the Tumour Angiogenesis Research Group. *J Clin Oncol.* 2006; 24(26): 4301–8.
16. **Li F, Xiang H, Pang Z, et al.** Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis. *Cancer Med.* 2020; 9(19): 7341–51.
17. **Epstein JI, Egevad L, Srigley JR, Humphrey PA.** The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol.* 2016; 40(2): 244–52.
18. **Karnofsky DA, Burchenal JH.** Present status of clinical cancer chemotherapy. *Am J Med.* 1950; 8(6): 767–88.
19. **Oken MM, Creech RH, Tormey DC, et al.** Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* 1982; 5(6): 649–55.
20. **Kapoor R, Saxena AK, Vasudev P, Sundriyal D, Kumar A.** Cancer induced bone pain: current management and future perspectives. *Med Oncol.* 2021; 38(11): 134.
21. **Zajączkowska R, Kocot-Kępska M, Leppert W, Wordliczek J.** Bone Pain in Cancer Patients: Mechanisms and Current Treatment. *Int J Mol Sci.* 2019; 20(23): 6047.
22. **Yoong J, Poon P.** Principles of cancer pain management: An overview and focus on pharmacological and interventional strategies. *Aust J Gen Pract.* 2018; 47(11): 758–62.
23. **Batson OV.** The function of the vertebral veins and their role in the spread of metastases. *Ann Surg.* 1940; 112(1): 138–49.
24. **Smith AE, Muralidharan A, Smith MT.** Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials. *Discov Oncol.* 2022; 13(1): 108.
25. **Yoneda T, Hiasa M, Nagata Y, Okui T, White FA.** Acidic microenvironment and bone pain in cancer-colonized bone. *Bonekey Rep.* 2015; 4: 690.
26. **Halabi S, Vogelzang NJ, Kornblith AB, et al.** Pain Predicts Overall Survival in Men with Metastatic Castration-Refractory Prostate Cancer. *J Clin Oncol.* 2008; 26(15): 2544–9.
27. **Jenšovský J.** Sarkopenie: definice a diagnostika nové nemoci. *Clin Osteol.* 2019; 24(1): 14–18.
28. **Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al.** Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing.* 2010; 39(4): 412–23.